Alnylam to share progress across its transthyretin amyloidosis franchise including additional analyses of the helios-b phase 3 study results at heart failure 2025 congress

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the company will present the latest data from its flagship transthyretin amyloidosis (ttr) franchise at the upcoming heart failure 2025 congress, a scientific congress of the european society of cardiology, taking place may 17-20 in belgrade, serbia. the latest analyses of the helios-b phase 3 study of vutrisiran in patients with attr amyloidosis with card.
ALNY Ratings Summary
ALNY Quant Ranking